Welcome to our dedicated page for Verona Pharma news (Ticker: VRNA), a resource for investors and traders seeking the latest updates and insights on Verona Pharma stock.
Verona Pharma plc (VRNA) is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for respiratory diseases that have significant unmet medical needs. Headquartered in both the United States and the United Kingdom, Verona Pharma is publicly traded on the NASDAQ Global Market and the London Stock Exchange.
The company's flagship product, Ensifentrine, is currently in development for the treatment of chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF). Ensifentrine is a dual inhibitor that has demonstrated potential in reducing inflammation and relaxing airway muscles, addressing critical gaps in the treatment of these chronic diseases. In addition to COPD and CF, Verona Pharma aims to expand its therapeutic pipeline to include treatments for other respiratory conditions such as asthma.
Verona Pharma's success is underpinned by a team of seasoned experts with extensive backgrounds in the discovery, development, and commercialization of respiratory therapies. The company has also forged strong partnerships with leading research institutions and advocacy organizations in the respiratory health sector. These collaborations have been instrumental in advancing their clinical programs and have garnered Verona Pharma several awards for innovation.
Recent achievements include the successful completion of Phase 2 clinical trials for Ensifentrine, which showed promising results in improving lung function and reducing symptoms in COPD patients. The company is now steering towards Phase 3 trials, marking a significant milestone in its mission to bring effective treatments to market.
Financially, Verona Pharma has demonstrated stability and growth, strengthening its financial flexibility through strategic funding rounds. This robust financial health supports ongoing research and development activities, ensuring sustained progress in their clinical programs. The company’s near-term goals include advancing Ensifentrine into late-stage clinical trials and exploring potential marketing authorizations.
For the latest updates on Verona Pharma’s research, financial performance, and upcoming milestones, stay tuned to the latest news and press releases.
Verona Pharma announces the reporting of top-line Phase 3 data from its ENHANCE-2 trial on August 9, 2022. This trial evaluates the efficacy of nebulized ensifentrine for the treatment of COPD. The company will also disclose its financial results for Q2 2022 during an investment community webcast at 8:30 a.m. EDT. Notably, the ENHANCE program includes two studies focused on lung function improvements over 24 weeks, with primary endpoints measuring FEV1. Verona Pharma seeks to address significant unmet needs in respiratory diseases.
Verona Pharma (Nasdaq: VRNA) will announce its second-quarter financial results for the period ending June 30, 2022, on August 15, 2022. A conference call for investors is scheduled for 9:00 a.m. EDT to discuss these results and provide updates on the company’s operations. Verona Pharma is a clinical-stage biopharmaceutical company dedicated to developing therapies for respiratory diseases, specifically through its product candidate, ensifentrine, which is currently in Phase 3 trials for COPD maintenance treatment.
Verona Pharma has completed patient enrollment for its Phase 3 ENHANCE clinical trials, with over 800 subjects in the ENHANCE-1 trial and more than 1,600 across both ENHANCE-1 and ENHANCE-2 trials for ensifentrine, targeting chronic obstructive pulmonary disease (COPD).
Top-line data is anticipated in Q3 2022 and late 2022. The study aims to demonstrate the efficacy of ensifentrine in improving lung function and quality of life for COPD patients, potentially marking a significant advancement in treatment options.
Verona Pharma plc (Nasdaq: VRNA) will host an in-person KOL event on June 16, 2022, at 8:00 AM ET in New York. The event will feature discussions on COPD treatment, focusing on unmet needs and the potential of ensifentrine. Key opinion leaders, Igor Bajaktarevic and Jill Ohar, will share insights. Verona Pharma also plans to release top-line Phase 3 ENHANCE data for COPD in Q3 2022. Ensifentrine aims to be a first-in-class therapy, combining bronchodilator and anti-inflammatory effects. For details, visit www.veronapharma.com.
Verona Pharma (Nasdaq: VRNA) will have its Senior Vice President of Commercial, Chris Martin, present at the Jefferies Healthcare Conference on June 8, 2022, at 1:30 PM ET. This event will be accessible via a webcast on the company's website. Verona Pharma is a clinical-stage biopharmaceutical company focused on respiratory diseases, currently evaluating nebulized ensifentrine in a Phase 3 clinical program for COPD. Top-line data for this study is anticipated in the third quarter of 2022, with ensifentrine aiming to be a dual-action therapy.
Verona Pharma plc (Nasdaq: VRNA) presented an abstract at the American Thoracic Society International Conference in May 2022, confirming that ensifentrine met all safety objectives in a thorough QT study. The findings, which indicated no significant effects on cardiac conduction, support Verona's upcoming New Drug Application for ensifentrine as a treatment for chronic obstructive pulmonary disease (COPD). The FDA requires such studies for new drug submissions, enhancing the potential for ensifentrine's approval.
Verona Pharma (Nasdaq: VRNA) announced its participation in two key conferences in May 2022. The LifeSci Partners Virtual Immunology & Inflammation Symposium will take place on May 10 at 9:00 AM ET, and the H.C. Wainwright Hybrid Global Investment Conference is scheduled for May 24 at 3:30 PM ET in Miami. Verona Pharma is advancing its Phase 3 clinical program for nebulized ensifentrine, aimed at COPD treatment, with expected top-line data in Q3 2022. Ensifentrine could potentially be a breakthrough therapy combining bronchodilator and anti-inflammatory properties.
Verona Pharma (VRNA) reported its Q1 2022 financial results, highlighting significant progress in its Phase 3 ENHANCE clinical trials for COPD treatment, with 90% enrollment completion. The company anticipates top-line data from ENHANCE-2 in Q3 2022 and plans to submit a New Drug Application to the FDA in H1 2023, pending positive results. Cash and equivalents were $132.8 million as of March 31, 2022, expected to fund operations through 2023. However, net loss increased to $24.8 million from $21.3 million year-over-year.
Verona Pharma plc (Nasdaq: VRNA) announced it will report its financial results for Q1 2022 on May 3, 2022, followed by a conference call at 9:00 a.m. EDT. The company focuses on treatments for respiratory diseases, with its key product candidate ensifentrine undergoing Phase 3 clinical trials for COPD. Ensifentrine may offer unique bronchodilator and anti-inflammatory effects. The call can be accessed via telephone or a live webcast available on the company's website. For more details, visit www.veronapharma.com.
Verona Pharma plc (Nasdaq: VRNA) announces the appointment of Mr. James Brady as a Non-Executive Director, enhancing its board with his extensive experience in the biopharmaceutical industry. Brady's career spans over 30 years at AstraZeneca, including his role as Chief Financial Officer of MedImmune, contributing to significant product development. Concurrently, Dr. Andrew Sinclair will step down from the board after the Annual General Meeting on April 27, 2022. Verona Pharma is progressing its commercialization plans for ensifentrine, a novel respiratory therapy.
FAQ
What is the current stock price of Verona Pharma (VRNA)?
What is the market cap of Verona Pharma (VRNA)?
What is Verona Pharma plc?
What is Ensifentrine?
What diseases does Verona Pharma target?
Where is Verona Pharma listed?
Who leads Verona Pharma?
What recent achievements has Verona Pharma made?
What are Verona Pharma’s near-term milestones?
Does Verona Pharma have any partnerships?
What awards has Verona Pharma received?
How can I stay updated on Verona Pharma?
